Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133

Area of Science:

• Endocrinology and Metabolism
• Pharmacology and Drug Discovery
• Immunology and Autoimmune Diseases

Background:

• Autoimmune destruction of pancreatic beta-cells leads to insulin deficiency, hyperglycemia, and diabetes.
• Enhancing beta-cell mass and function is a potential therapeutic strategy for diabetes intervention.
• Targeting pathways that regulate beta-cell proliferation may offer novel treatment approaches.

Purpose of the Study:

• To discover and characterize a potent and selective inhibitor of DYRK1A for potential diabetes therapy.
• To evaluate the efficacy of the identified compound in promoting beta-cell proliferation both in vitro and in vivo.
• To assess the therapeutic potential of the compound in improving glucose homeostasis and insulin secretion.

Main Methods:

• High-throughput screening and lead optimization to identify a DYRK1A inhibitor (GNF2133) from a 6-azaindole scaffold.
• In vitro studies using rodent and human beta-cells to assess proliferation.
• In vivo studies in RIP-DTA mice to evaluate glucose disposal and insulin secretion following GNF2133 administration.

Main Results:

• GNF2133 was identified as a potent and selective DYRK1A inhibitor.
• GNF2133 demonstrated significant proliferation of both rodent and human beta-cells in vitro.
• In vivo, GNF2133 showed dose-dependent glucose disposal capacity and enhanced insulin secretion in response to a GPAIS challenge in mice.

Conclusions:

• The DYRK1A inhibitor GNF2133 promotes beta-cell proliferation and improves glucose homeostasis.
• This compound represents a promising therapeutic candidate for type 1 diabetes (T1D) by addressing beta-cell deficiency.
• The findings open new avenues for disease-altering therapeutic interventions in diabetes treatment.